{"protocolSection":{"identificationModule":{"nctId":"NCT04667637","orgStudyIdInfo":{"id":"Y(2020)045"},"organization":{"fullName":"General Hospital of Shenyang Military Region","class":"OTHER"},"briefTitle":"Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol","officialTitle":"Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol (INSIST-ED): a Prospective, Randomized, Double Blinded, Multi-centre Study"},"statusModule":{"statusVerifiedDate":"2022-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-02-23","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-10-10","type":"ACTUAL"},"completionDateStruct":{"date":"2022-10-10","type":"ACTUAL"},"studyFirstSubmitDate":"2020-12-08","studyFirstSubmitQcDate":"2020-12-08","studyFirstPostDateStruct":{"date":"2020-12-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-10-09","lastUpdatePostDateStruct":{"date":"2022-10-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Hui-Sheng Chen","investigatorTitle":"Director","investigatorAffiliation":"General Hospital of Shenyang Military Region"},"leadSponsor":{"name":"Hui-Sheng Chen","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received endovascular thrombectomy."},"conditionsModule":{"conditions":["Stroke","Endovascular Thrombectomy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":200,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"0.9% NaCl","type":"PLACEBO_COMPARATOR","description":"Intravenous injections of 0.9% NaCl BID for 12 ±2days.","interventionNames":["Drug: edaravone dexborneol"]},{"label":"Edaravone Dexborneol","type":"EXPERIMENTAL","description":"Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 12 ±2days.","interventionNames":["Drug: edaravone dexborneol"]}],"interventions":[{"type":"DRUG","name":"edaravone dexborneol","description":"Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.","armGroupLabels":["0.9% NaCl","Edaravone Dexborneol"],"otherNames":["edaravone deborbeol placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of patients with modified Rankin Score 0 to 2","description":"Proportion of patients with modified Rankin Score 0 to 2","timeFrame":"Day 90"}],"secondaryOutcomes":[{"measure":"Proportion of patients with modified Rankin Score 0 to 1","description":"Proportion of patients with modified Rankin Score 0 to 1","timeFrame":"Day 90"},{"measure":"Distribution of modified Rankin Score","description":"Distribution of modified Rankin Score after the treatment","timeFrame":"Day 90"},{"measure":"Changes in National Institute of Health stroke scale (NIHSS)","description":"the minimum and maximum values of NIHSS are 42 and 0, respectively; higher NIHSS mean a worse outcome","timeFrame":"24 hours, 48 hours, and 2 weeks"},{"measure":"Change in infarct volume","description":"infarct volume is determinted by CT or DWI","timeFrame":"1 week"}],"otherOutcomes":[{"measure":"Proportion of symptomatic intracranial hemorrhage (sICH)","description":"sICH was defined as 4 or more increase in NIHSS caused by hemorrhage","timeFrame":"48 hours"},{"measure":"Proportion of intraparenchymal hemorrhage (PH1 and PH2)","description":"Proportion of PH1 and PH2 within 48 hours after the treatment","timeFrame":"48 hours"},{"measure":"Proportion of death","description":"death due to any cause","timeFrame":"Day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. 18 to 80 years of age;\n2. Patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation and met the criteria of mechanical thrombectomy;\n3. Sufficient recanalization within 9 hours of stroke onset;\n4. Sufficient recanalization （TICI 2b-3）;\n5. Acute ischemic stroke with neurological baseline deficit equivalent to the National Institute of Health Stroke Scale (NIHSS) ≥ 6 before recanalization treatment;\n6. First ever stroke or mRS≤1 after previous disease\n7. The availability of informed consent.\n\nExclusion Criteria:\n\n1. Acute ischemic stroke patients with insufficient recanalization（TICI \\< 2a）\n2. Hemorrhagic transformation (PH2) indicated by NCCT performed after the operation immediately;\n3. Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;\n4. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ \\<100000/mm3）;\n5. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n6. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n7. Patients with malignant tumor or under antineoplastic therapy with estimated lifetime less than 3 months;\n8. Pregnancy, plan to get pregnant or during lactation;\n9. Patients with contraindication or allergic to any ingredient of drugs in our study;\n10. Unsuitable for this clinical studies assessed by researcher.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"General Hospital of Northern Theater Command","city":"ShenYang","zip":"110840","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}}]},"ipdSharingStatementModule":{"ipdSharing":"YES"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077553","term":"Edaravone"}],"ancestors":[{"id":"D000016166","term":"Free Radical Scavengers"},{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M1831","name":"Edaravone","asFound":"Lay","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}